Despite a significant revenue drop, Moderna Inc (MRNA) focuses on financial discipline and pipeline growth to drive future ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

Shares of Moderna, Inc. (MRNA) traded over 6% lower on Thursday morning after the company reported a decline in first-quarter ...

Moderna MRNA incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Moderna (MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects ...

jetMESSENGER ® reagent considerably outstrips Lipofectamine ™ 2000 transfection reagent in T cells, reaching more elevated GFP expression while preserving cell integrity. In B cells, it shows superior ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

Discover six hemophilia companies developing new treatments for the genetic bleeding disorder, from gene therapies to RNAi ...